

ENHANCING DRUG DEVELOPMENT THROUGH ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING

ISCTM ANNUAL MEETING, 19 FEBRUARY 2020, WASHINGTON, DC



ENHANCING DRUG DEVELOPMENT THROUGH ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING

- Employee of Koneksa Health
- Stockholder in Signant Health



Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD)

PROPOSED REGULATORY FRAMEWORK FOR MODIFICATIONS TO ARTIFICIAL INTELLIGENCE/MACHINE LEARNING (AI/ML)-BASED SOFTWARE AS A MEDICAL DEVICE (SAMd). FDA, APRIL 2019.

“EXAMPLE HIGH-VALUE APPLICATIONS INCLUDE EARLIER DISEASE DETECTION, MORE ACCURATE DIAGNOSIS, IDENTIFICATION OF NEW OBSERVATIONS OR PATTERNS ON HUMAN PHYSIOLOGY, AND DEVELOPMENT OF PERSONALIZED DIAGNOSTICS AND THERAPEUTICS.”

PROPOSED REGULATORY FRAMEWORK FOR MODIFICATIONS TO ARTIFICIAL INTELLIGENCE/MACHINE LEARNING (AI/ML)-BASED SOFTWARE AS A MEDICAL DEVICE (SAMD). FDA, APRIL 2019.



ON ARTIFICIAL INTELLIGENCE - A EUROPEAN APPROACH TO EXCELLENCE AND TRUST

- Action 6: The Commission will initiate open and transparent sector dialogues giving priority to **healthcare**, rural administrations and public service operators in order to present an action plan to facilitate development, experimentation and adoption. The sector dialogues will be used to prepare a specific 'Adopt AI programme' that will support public procurement of AI systems, and help to transform public procurement processes themselves.



ENHANCING DRUG DEVELOPMENT THROUGH ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING

